Merck Partner Joins Forces With Emergent Bio To Increase Access To Ebola Treatment

Emergent BioSolutions Inc  (NYSE: EBS ) has agreed to create a collaboration  with Ridgeback Biotherapeutics  to expand the availability of Ebanga (Ansuvimab-zykl).  FDA approved Ebanga in December 2020 for Ebola. Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga in the U.S. ... Full story available on